Swedbank AB Has $5.13 Million Stake in Savara Inc. $SVRA

Swedbank AB grew its holdings in shares of Savara Inc. (NASDAQ:SVRA) by 54.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 850,000 shares of the company’s stock after acquiring an additional 300,000 shares during the quarter. Swedbank AB’s holdings in Savara were worth $5,126,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Savara by 48.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after acquiring an additional 3,205 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after acquiring an additional 9,463 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new position in Savara during the third quarter worth about $44,000. Prudential Financial Inc. acquired a new position in Savara during the second quarter worth about $30,000. Finally, BNP Paribas Financial Markets raised its stake in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after acquiring an additional 4,626 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. Oppenheimer assumed coverage on Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective on the stock. William Blair set a $10.00 price objective on Savara in a report on Monday, March 16th. HC Wainwright reissued a “buy” rating on shares of Savara in a report on Monday, March 16th. Finally, Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.13.

Savara Trading Up 1.4%

NASDAQ SVRA opened at $5.23 on Friday. The company has a quick ratio of 11.85, a current ratio of 11.85 and a debt-to-equity ratio of 0.15. Savara Inc. has a twelve month low of $1.89 and a twelve month high of $7.01. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -9.87 and a beta of 0.28. The business’s fifty day moving average is $5.43 and its 200 day moving average is $5.45.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, sell-side analysts expect that Savara Inc. will post -0.51 EPS for the current fiscal year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.